A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea

NCT ID: NCT00000980

Last Updated: 2005-06-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL

Brief Summary

To determine the safety and effectiveness of intravenous spiramycin in patients with AIDS-related cryptosporidial diarrhea.

Spiramycin, a macrolide antibiotic, has been studied in the United States for the treatment of cryptosporidial diarrhea. Some reports suggest that spiramycin is useful in improving the symptoms of cryptosporidial diarrhea in some patients. Results of one study, however, showed no significant difference between spiramycin and placebo (inactive medication). A later study indicated that the absorption of spiramycin is significantly decreased when food is present. Thus, the results of the trial may have been due to poor absorption of spiramycin.

Detailed Description

Spiramycin, a macrolide antibiotic, has been studied in the United States for the treatment of cryptosporidial diarrhea. Some reports suggest that spiramycin is useful in improving the symptoms of cryptosporidial diarrhea in some patients. Results of one study, however, showed no significant difference between spiramycin and placebo (inactive medication). A later study indicated that the absorption of spiramycin is significantly decreased when food is present. Thus, the results of the trial may have been due to poor absorption of spiramycin.

Patients are observed for 3 days to establish baseline conditions. They are informed that the treatment period is 21 days during which they receive 15 days of spiramycin and 6 consecutive days of placebo; they are not told which 6-day period they receive placebo. All patients receive 15 days of spiramycin. Patients who do not have a favorable response are treated with a higher dose of spiramycin for an additional 15 days. Responders at either dose are followed weekly for 4 weeks. Should a relapse occur, patients receive an additional 15 days of therapy, at the dose of spiramycin that initially produced a response, following reestablishment of a baseline with 6 days of placebo. Nonresponders to the higher dose are taken off the study.

Conditions

Cryptosporidiosis; HIV Infections

Study Design

• Primary Study Purpose: TREATMENT

Interventions

Spiramycin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

• Vitamin supplements.
• Zidovudine (AZT) for patients previously taking AZT. However, dosing with spiramycin should be delayed until the dose of AZT has stabilized. The dose may be decreased for AZT-associated toxicity.

Allowed for diarrhea:

• Loperamide hydrochloride capsules (2 mg) or loperamide hydrochloride liquid (1 mg/5 ml).

Allowed for nausea:

• Sucralfate and metoclopramide hydrochloride.

Allowed for vomiting:

• Prochlorperazine and trimethobenzamide hydrochloride.
• Allowed as prophylaxis for Pneumocystis carinii pneumonia (PCP):
• Aerosolized pentamidine.

Patients must have:

• A diagnosis of AIDS according to the CDC.
• Chronic diarrhea.
• Presence of Cryptosporidium oocysts in stool specimen. Patients or a legally authorized representative must sign an informed consent form. Diet will be lactose free, maximum 7 g fat/day with unlimited calorie intake. Patients who require total parenteral nutrition will also be allowed oral intake.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

• Grade 4 (for hematologic) or Grade 3 (for all other) toxicity.
• Known sensitivity to macrolide antibiotics.
• Presence of other diarrhea-causing pathogens.
• Active opportunistic infection requiring systemic antimicrobial therapy.
• Toxicity grades according to NIAID toxicity scale for adults.

Concurrent Medication:

Excluded:

• Other investigational drugs.
• Cancer chemotherapy.
• Alpha interferon.
• Other immunomodulating agents.
• Other macrolide antibiotics.
• Trimethoprim / sulfamethoxazole.
• Ganciclovir.
• H2 blockers and AL-721.
• Medications known to cause gastrointestinal irritation or alteration of gastrointestinal motility or absorption should be avoided if possible.
• Zidovudine (AZT) therapy may not be initiated and the dose may not be increased during the study.

Patients with the following are excluded:

• Grade 4 (for hematologic) or Grade 3 (for all other) toxicity.
• Known sensitivity to macrolide antibiotics.
• Presence of other diarrhea-causing pathogens.
• Active opportunistic infection requiring systemic antimicrobial therapy.
• Toxicity grades according to NIAID toxicity scale for adults.

Prior Medication:

Excluded within 7 days of study entry:

• Investigational drugs.

Excluded within 14 days of study entry:

• Cancer chemotherapy.
• Alpha interferon.
• Other immunomodulating agents.
• Other macrolide antibiotics.
• Trimethoprim / sulfamethoxazole.
• Ganciclovir.

• Minimum Eligible Age: 13 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: collaborator

Rhone-Poulenc Rorer

INDUSTRY

Sponsor Role: lead

Principal Investigators

R Soave

Role: STUDY_CHAIR

Locations

Kaiser Permanente Med Ctr

San Diego, California, United States

Johns Hopkins Univ School of Medicine

Baltimore, Maryland, United States

Univ of Massachusetts Med Ctr

Worcester, Massachusetts, United States

Bellevue Hosp / New York Univ Med Ctr

New York, New York, United States

Cornell Univ Med Ctr

New York, New York, United States

Univ Hosp of Cleveland / Case Western Reserve Univ

Cleveland, Ohio, United States

Nelson Tebedo Community Clinic

Dallas, Texas, United States

Countries

United States

Other Identifiers

FDA 28A

Identifier Type: -

Identifier Source: secondary_id

CCB-301

Identifier Type: -

Identifier Source: secondary_id

ACTG 113

Identifier Type: -

Identifier Source: org_study_id